Metabotropic Glutamate Receptors 2 and 3 As Targets for Treating Nicotine Addiction

Overview

Journal Biol Psychiatry

Publisher Elsevier

Specialty Psychiatry

Date 2018 Jan 6

PMID 29301614

Citations 14

Authors

Alan J Cross

Robert Anthenelli

Xia Li

Affiliations

Soon will be listed here.

Abstract

Tobacco smoking, driven by the addictive properties of nicotine, continues to be a worldwide health problem. Based on the well-established role of glutamatergic neurotransmission in drug addiction, novel medication development strategies seek to halt nicotine consumption and prevent relapse to tobacco smoking by modulating glutamate transmission. The presynaptic inhibitory metabotropic glutamate receptors 2 and 3 (mGluR2/3) are key autoreceptors on glutamatergic terminals that maintain glutamate homeostasis. Accumulating evidence suggests the critical role of mGluR2/3 in different aspects of nicotine addiction, including acquisition and maintenance of nicotine taking, nicotine withdrawal, and persistent nicotine seeking even after prolonged abstinence. The involvement of mGluR2/3 in other neuropsychiatric conditions, such as anxiety, depression, schizophrenia, Alzheimer's disease, Parkinson's disease, and pain, provides convincing evidence suggesting that mGluR2/3 may provide an effective therapeutic approach for comorbidity of smoking and these conditions. This focused review article highlights that mGluR2/3 provide a promising target in the search for smoking cessation medication with novel mechanisms of actions that differ from those of currently U.S. Food and Drug Administration-approved pharmacotherapies.

Citing Articles

Evolutionary and functional analysis of metabotropic glutamate receptors in lampreys.

Zhuang R, Yan Z, Gao Y, Nurmamat A, Zhang S, Xiu M Fish Physiol Biochem. 2024; 50(4):1861-1877.

PMID: 38951427 DOI: 10.1007/s10695-024-01374-x.

Neurogenetic underpinnings of nicotine use severity: Integrating the brain transcriptomes and GWAS variants via network approaches.

Yang B, Xiang B, Wang T, Ma S, Li C Psychiatry Res. 2024; 334:115815.

PMID: 38422867 PMC: 11017751. DOI: 10.1016/j.psychres.2024.115815.

New medications development for smoking cessation.

Lengel D, Kenny P Addict Neurosci. 2023; 7.

PMID: 37519910 PMC: 10373598. DOI: 10.1016/j.addicn.2023.100103.

Intrauterine Smoke Exposure, microRNA Expression during Human Lung Development, and Childhood Asthma.

Rosenberg L, Liu C, Sharma R, Wood C, Vyhlidal C, Gaedigk R Int J Mol Sci. 2023; 24(9).

PMID: 37175432 PMC: 10178351. DOI: 10.3390/ijms24097727.

Are mGluR2/3 Inhibitors Potential Compounds for Novel Antidepressants?.

Jiang Y, Zou M, Ren T, Wang Y Cell Mol Neurobiol. 2022; 43(5):1931-1940.

PMID: 36443586 PMC: 10287579. DOI: 10.1007/s10571-022-01310-8.

References

Sidique S, Dhanya R, Sheffler D, Nickols H, Yang L, Dahl R . Orally active metabotropic glutamate subtype 2 receptor positive allosteric modulators: structure-activity relationships and assessment in a rat model of nicotine dependence. J Med Chem. 2012; 55(22):9434-45. PMC: 3508153. DOI: 10.1021/jm3005306. View

Acri J, Cross A, Skolnick P . From bench to bedside: mGluR2 positive allosteric modulators as medications to treat substance use disorders. Psychopharmacology (Berl). 2016; 234(9-10):1347-1355. DOI: 10.1007/s00213-016-4501-9. View

Xie X, Steketee J . Repeated exposure to cocaine alters the modulation of mesocorticolimbic glutamate transmission by medial prefrontal cortex Group II metabotropic glutamate receptors. J Neurochem. 2008; 107(1):186-96. PMC: 2574769. DOI: 10.1111/j.1471-4159.2008.05593.x. View

Knackstedt L, LaRowe S, Mardikian P, Malcolm R, Upadhyaya H, Hedden S . The role of cystine-glutamate exchange in nicotine dependence in rats and humans. Biol Psychiatry. 2008; 65(10):841-5. PMC: 2756612. DOI: 10.1016/j.biopsych.2008.10.040. View

Peters J, Kalivas P . The group II metabotropic glutamate receptor agonist, LY379268, inhibits both cocaine- and food-seeking behavior in rats. Psychopharmacology (Berl). 2006; 186(2):143-9. DOI: 10.1007/s00213-006-0372-9. View

Shen K, Johnson S . Group II metabotropic glutamate receptor modulation of excitatory transmission in rat subthalamic nucleus. J Physiol. 2003; 553(Pt 2):489-96. PMC: 2343573. DOI: 10.1113/jphysiol.2003.052209. View

Jonkman S, Risbrough V, Geyer M, Markou A . Spontaneous nicotine withdrawal potentiates the effects of stress in rats. Neuropsychopharmacology. 2007; 33(9):2131-8. PMC: 2648847. DOI: 10.1038/sj.npp.1301607. View

Mansvelder H, McGehee D . Long-term potentiation of excitatory inputs to brain reward areas by nicotine. Neuron. 2000; 27(2):349-57. DOI: 10.1016/s0896-6273(00)00042-8. View

Liechti M, Markou A . Metabotropic glutamate 2/3 receptor activation induced reward deficits but did not aggravate brain reward deficits associated with spontaneous nicotine withdrawal in rats. Biochem Pharmacol. 2007; 74(8):1299-307. DOI: 10.1016/j.bcp.2007.05.020. View

10.

Balfour D . The neuronal pathways mediating the behavioral and addictive properties of nicotine. Handb Exp Pharmacol. 2009; (192):209-33. DOI: 10.1007/978-3-540-69248-5_8. View

11.

Olive M . Metabotropic glutamate receptor ligands as potential therapeutics for addiction. Curr Drug Abuse Rev. 2009; 2(1):83-98. PMC: 2717506. DOI: 10.2174/1874473710902010083. View

12.

Rose J . Nicotine and nonnicotine factors in cigarette addiction. Psychopharmacology (Berl). 2005; 184(3-4):274-85. DOI: 10.1007/s00213-005-0250-x. View

13.

Nisell M, Nomikos G, Svensson T . Systemic nicotine-induced dopamine release in the rat nucleus accumbens is regulated by nicotinic receptors in the ventral tegmental area. Synapse. 1994; 16(1):36-44. DOI: 10.1002/syn.890160105. View

14.

Reichel C, Bevins R . Forced abstinence model of relapse to study pharmacological treatments of substance use disorder. Curr Drug Abuse Rev. 2009; 2(2):184-94. PMC: 2916179. DOI: 10.2174/1874473710902020184. View

15.

Shiffman S, Balabanis M, Gwaltney C, Paty J, Gnys M, Kassel J . Prediction of lapse from associations between smoking and situational antecedents assessed by ecological momentary assessment. Drug Alcohol Depend. 2007; 91(2-3):159-68. PMC: 2244586. DOI: 10.1016/j.drugalcdep.2007.05.017. View

16.

Karasawa J, Yoshimizu T, Chaki S . A metabotropic glutamate 2/3 receptor antagonist, MGS0039, increases extracellular dopamine levels in the nucleus accumbens shell. Neurosci Lett. 2005; 393(2-3):127-30. DOI: 10.1016/j.neulet.2005.09.058. View

17.

Fu Y, Matta S, Gao W, Brower V, Sharp B . Systemic nicotine stimulates dopamine release in nucleus accumbens: re-evaluation of the role of N-methyl-D-aspartate receptors in the ventral tegmental area. J Pharmacol Exp Ther. 2000; 294(2):458-65. View

18.

Zvolensky M, Stewart S, Vujanovic A, Gavric D, Steeves D . Anxiety sensitivity and anxiety and depressive symptoms in the prediction of early smoking lapse and relapse during smoking cessation treatment. Nicotine Tob Res. 2009; 11(3):323-31. PMC: 2666379. DOI: 10.1093/ntr/ntn037. View

19.

Paterson N, Semenova S, Gasparini F, Markou A . The mGluR5 antagonist MPEP decreased nicotine self-administration in rats and mice. Psychopharmacology (Berl). 2003; 167(3):257-64. DOI: 10.1007/s00213-003-1432-z. View

20.

Litman R, Smith M, Doherty J, Cross A, Raines S, Gertsik L . AZD8529, a positive allosteric modulator at the mGluR2 receptor, does not improve symptoms in schizophrenia: A proof of principle study. Schizophr Res. 2016; 172(1-3):152-7. DOI: 10.1016/j.schres.2016.02.001. View